🇺🇸 FDA
Pipeline program

Hydroxyurea

ERB0002

Phase 2 small_molecule active

Quick answer

Hydroxyurea for Thalassemia, Beta is a Phase 2 program (small_molecule) at Sana Biotechnology with 1 ClinicalTrials.gov record(s).

Program details

Company
Sana Biotechnology
Indication
Thalassemia, Beta
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials